Metabolomics Market Report 2026

The metabolomics market size has grown rapidly in recent years. It will grow from $4.17 billion in 2025 to $4.9 billion in 2026 at a compound annual growth rate (CAGR) of 17.5%. The growth in the historic period can be attributed to growing biomarker discovery research, increasing mass spectrometry adoption, rise in cancer metabolism studies, expanding chromatography system usage, growth in metabolite profiling techniques.

The metabolomics market size is expected to see rapid growth in the next few years. It will grow to $9.29 billion in 2030 at a compound annual growth rate (CAGR) of 17.3%. The growth in the forecast period can be attributed to advances in bioinformatics tools, rising focus on personalized medicine, increasing demand for nutrigenomics applications, growth in metabolic pathway research, expanding clinical diagnostics integration. Major trends in the forecast period include integration of precision medicine with metabolomic profiling, expansion of cloud-based metabolomics data platforms, AI-driven metabolite pattern recognition, automation in high-throughput metabolomics workflows, iot-enabled real-time metabolic monitoring.

The increasing prevalence of cancer is expected to drive the growth of the metabolomics market in the coming years. Cancer is a collection of diseases characterized by abnormal cell growth, tissue invasion, and the potential to spread to other parts of the body. The rising incidence of cancer is largely attributed to an aging population, as advanced age is the most significant risk factor for most cancer types, with the majority of cases occurring in individuals over 65 years old. Metabolomics supports cancer research by offering a detailed overview of metabolic alterations in tumor cells, enabling early detection, insights into disease mechanisms, and the identification of potential therapeutic targets. For example, in February 2024, the World Health Organization, a Switzerland-based international organization focused on global health policy and public health initiatives, projected over 35 million new cancer cases by 2050, marking a 77% increase from the estimated 20 million cases in 2022. Consequently, the growing prevalence of cancer is fueling the expansion of the metabolomics market.

Key players in the metabolomics market are concentrating on the development of Integrated Bioinformatics Platforms to enhance the interpretation of complex metabolomic data, thereby advancing personalized medicine, biomarker discovery, and disease research. An Integrated Bioinformatics Platform is a comprehensive software solution that combines multiple bioinformatics tools and databases to support the analysis and interpretation of biological data. Researchers can align metabolomics data with Metabolon’s detailed biochemical pathway maps, helping to uncover underlying biological processes and disease mechanisms. For instance, in February 2024, Metabolon, Inc., a US-based company, introduced Metabolon’s bioinformatics platform. The platform’s Biomarker Lenses feature allows users to apply advanced analytical filters to focus on metabolites associated with specific pathways or diseases, enabling a more targeted analysis of metabolomic data. It also provides tools for statistical analyses, including T-tests and ANOVAs, allowing researchers to build and compare models, manage metadata, and visualize results efficiently.

In June 2025, Bruker Corporation, a US-based scientific instruments and life-science technology company, acquired biocrates life sciences ag for an undisclosed sum. Through this acquisition, Bruker aims to enhance its multiomics portfolio by integrating metabolomics, thereby expanding its offerings beyond instruments to include standardized metabolite-analysis kits, assays, software, and services. Biocrates Life Sciences Ag, an Austria-based life-science technology firm, specializes in mass-spectrometry-based quantitative metabolite and lipid analysis, providing standardized kits, software, and contract research services that enable laboratories to measure hundreds to thousands of metabolites from small biological samples.

Major companies operating in the metabolomics market are Human Metabolome Technologies Inc., Metabolon Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Agilent Technologies Inc., Thermo Fisher Scientific Inc., Waters Corporation, Biocrates Life Sciences AG, Shimadzu Corporation, Danaher Corporation, PerkinElmer Inc., LECO Corporation, Phenomenome Discoveries Inc., AB Sciex, BG Medicine Inc., Chenomx Inc., Creative Proteomics, Evotec A.G, Merck kgaA, Charles River Laboratories International Inc., Metabowerke GmbH, Metabolomic Diagnostics, Phenomenex Inc.

North America was the largest region in the metabolomics market in 2025. Western Europe was the second largest region in the metabolomics market. The regions covered in the metabolomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the metabolomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on analytical instruments, mass spectrometry equipment, and chromatography components have raised import costs and slowed procurement for research labs and pharmaceutical companies that rely heavily on international suppliers. Regions such as Asia-Pacific and South America face the greatest delays due to dependency on imported high-end metabolomics equipment. However, tariffs have encouraged domestic production of analytical systems, stimulated innovation in cost-efficient workflows, and pushed for localized manufacturing of reagents and consumables, reducing long-term reliance on foreign imports.

The metabolomics market research report is one of a series of new reports that provides metabolomics market statistics, including metabolomics industry global market size, regional shares, competitors with a metabolomics market share, detailed metabolomics market segments, market trends and opportunities, and any further data you may need to thrive in the metabolomics industry. This metabolomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Metabolomics is the study of small molecules called metabolites that are produced during metabolism within cells, tissues, or organisms. It provides insights into biological processes, disease mechanisms, and metabolic pathways by analyzing and quantifying these metabolites. This field is crucial in personalized medicine, drug discovery, and understanding various diseases like cancer and diabetes.

The main products and services of metabolomics are metabolomics instruments, metabolomics bioinformatics tools, and services. Metabolomics instruments are devices used to extensively examine low-molecular-weight compounds in biological samples. The various metabolomics instruments include separation techniques, detection techniques, and metabolomics bioinformatics tools and services involving bioinformatics tools and databases, as well as bioinformatics services. The different indications are cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and others that are applied in biomarker discovery, drug discovery, toxicology testing, nutrigenomics, functional genomics, personalized medicine, and others.

The metabolomics market includes revenue earned by liquid chromatography, gas chromatography, capillary electrophoresis, mass spectrometry, and nuclear magnetic resonance spectroscopy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.